Understand the source comparison
Peptides for Gut Inflammation: Efficacy Comparison
KPV (Lys-Pro-Val) Melanocortin receptor agonist; inhibits NF-κB translocation 40–55% reduction in IL-6, TNF-α in murine colitis models (Journal of Immunology, 2019) Oral (enteric-coated) or subcutaneous Most studied peptide for gut inflammation; oral bioavaila
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- KPV (Lys-Pro-Val)
- Melanocortin receptor agonist; inhibits NF-κB translocation
- 40–55% reduction in IL-6, TNF-α in murine colitis models (Journal of Immunology, 2019)
- Oral (enteric-coated) or subcutaneous
- Most studied peptide for gut inflammation; oral bioavailability requires enteric coating to survive gastric acid
- Thymalin-derived peptides
- T-cell differentiation modulation; reduces pro-inflammatory Th17 activity
- 35–50% reduction in IL-17A in IBD models (St. Petersburg Institute, 2022)
- Subcutaneous injection
- Broader immune regulation; targets upstream T-cell activation rather than local cytokine production
- BPC-157
- eNOS stabilisation; promotes angiogenesis and mucosal healing
- Limited direct cytokine data; accelerates ulcer healing by 60% in 14 days (gastric ulcer models)
- Oral or subcutaneous
- Mechanism is angiogenic, not immunomodulatory. Complements cytokine-targeting peptides but doesn't replace them
- LL-37 (human cathelicidin)
- Antimicrobial peptide; binds LPS to prevent TLR4 activation
- 30–45% reduction in LPS-induced IL-8 secretion (in vitro models)
- Topical or rectal administration
- Prevents bacterial translocation; most effective when bacterial overgrowth drives inflammation